Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07476105 | Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment | not yet recruiting | N/A | 170 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07529223 | Role of T Lymphocytes in Hypersensitivity Reactions to Asparaginase in Patients Treated for Acute Lymphoblastic Leukemia.(ASTRA) | not yet recruiting | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER |
| 1 |
| Apr 14, 2026 |
| clinicaltrials |
| NCT07529405 | A Study of VG712 in Patients With Mycosis Fungoides(CurbMF) | not yet recruiting | Phase 2 | 386 | Virogen Biotechnology Inc.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529951 | Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers | not yet recruiting | Phase 1 | 60 | Eilean TherapeuticsINDUSTRY | 0 | Apr 14, 2026 | clinicaltrials |
| NCT02944955 | A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) | not yet recruiting | Phase 2 | 52 | BioLite, Inc.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT05554419 | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) | not yet recruiting | Phase 2 | 184 | National Cancer Institute (NCI)NIH | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07469046 | VAH vs VA in Newly Diagnosed Elderly AML | not yet recruiting | Phase 3 | 308 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07525817 | A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma | not yet recruiting | — | 40 | Ou Bai, MD/PHDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07518940 | ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia(ENERGIA) | not yet recruiting | N/A | 25 | Carmen FavaOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07521124 | ABC Maintenance Therapy for AML(ABC-Maint) | not yet recruiting | N/A | 104 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07516353 | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults | not yet recruiting | N/A | 143 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07518654 | Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma(ThINKK-01) | not yet recruiting | Phase 1 | 12 | Michel DuvalOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07493330 | Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL | not yet recruiting | Phase 1 / Phase 2 | 86 | Ruijin HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07511062 | Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML | not yet recruiting | Phase 1 | 32 | Northside Hospital, Inc.OTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511114 | A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping | not yet recruiting | Phase 3 | 156 | Ruijin HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07509385 | The Role of Serum Cytokines IL_17 A and IL_10 in Disease Activity of Acute B Lymphoblastic Leukemia in South Egypt | not yet recruiting | — | 80 | Assiut UniversityOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT07510100 | Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(FUMANBA-04) | not yet recruiting | Phase 1 / Phase 2 | 17 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07221656 | Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration | not yet recruiting | — | 20 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07506668 | RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | not yet recruiting | Phase 1 / Phase 2 | 10 | Affiliated Hospital of Nantong UniversityOTHER | 0 | Apr 2, 2026 | clinicaltrials |
| NCT07507825 | Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)(VHAG) | not yet recruiting | Phase 2 | 61 | First People's Hospital of HangzhouOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07505160 | Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients | not yet recruiting | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505849 | ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma | not yet recruiting | Phase 2 | 100 | KeshuZhouOTHER_GOV | 0 | Apr 1, 2026 | clinicaltrials |
| NCT07498920 | Gut Microbiome in DLBCL Treated With Glofitamab | not yet recruiting | — | 30 | Peking Union Medical College HospitalOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07407140 | VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML(VAG-3+7-G) | not yet recruiting | Phase 3 | 300 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 25, 2026 | clinicaltrials |
| NCT07492407 | CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma | not yet recruiting | — | 131 | Henan Cancer HospitalOTHER_GOV | 0 | Mar 25, 2026 | clinicaltrials |
| NCT07489755 | TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients | not yet recruiting | Phase 3 | 180 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 0 | Mar 24, 2026 | clinicaltrials |
| NCT05969821 | Clonal Hematopoiesis of Immunological Significance(CHIS) | not yet recruiting | — | 5,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07485504 | Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies | not yet recruiting | Phase 1 | 15 | Tcelltech Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07486479 | Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | not yet recruiting | Phase 3 | 204 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07486726 | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07482761 | Multiple Myeloma t(4 ;14) FFPE Samples(MM-t4-14-FFPE) | not yet recruiting | — | 20 | BIWAKOINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07483749 | HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors | not yet recruiting | — | 400 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07476027 | Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07476378 | A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies(Archonc-001) | not yet recruiting | N/A | 69 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07476729 | International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) | not yet recruiting | Phase 3 | 750 | Charite University, Berlin, GermanyOTHER | 20 | Mar 17, 2026 | clinicaltrials |
| NCT07477366 | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 20 | ImmunityBio, Inc.INDUSTRY | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07477769 | Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)(NIPALYMPHO) | not yet recruiting | — | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07472621 | Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma | not yet recruiting | — | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07474961 | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.(BLOOD-dose) | not yet recruiting | Phase 4 | 400 | Anne Louise Tølbøll SørensenOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07463781 | Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy(NEURO_CAR-T) | not yet recruiting | — | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07372885 | GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia(GRACE) | not yet recruiting | Phase 1 / Phase 2 | 50 | University of ManchesterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07463768 | Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.(MIVONU) | not yet recruiting | Phase 2 | 60 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07464210 | Nemtabrutinib, Bortezomib, and Rituximab for WM | not yet recruiting | Phase 2 | 19 | Seoul National University HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07462299 | NUDT15/TPMT Multi-gene Guided 6-MP Dosing in Childhood ALL Maintenance Therapy | not yet recruiting | N/A | 110 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07457177 | Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL | not yet recruiting | Phase 2 | 40 | LIANG WANGOTHER | 0 | Mar 9, 2026 | clinicaltrials |
| NCT07458659 | Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(CART-BCMA) | not yet recruiting | Early Phase 1 | 3 | Chulalongkorn UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07060001 | Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker | not yet recruiting | Phase 2 | 112 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07456189 | The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating | not yet recruiting | N/A | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07449286 | IFN-α in Relapse Prevention. | not yet recruiting | Phase 2 | 100 | Peking University People's HospitalOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05565105 | CD34+ Transplants for Leukemia and Lymphoma | not yet recruiting | Phase 2 | 100 | Guenther KoehneOTHER | 1 | Mar 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 15, 2026source: clinicaltrials